Neko Health Secures $700 Million to Expand Preventive Health Service Amid Rising Demand
Neko Health has just wrapped up a significant $700 million Series C funding round, marking a pivotal moment for the company. This round was primarily led by Lightspeed Venture Partners, with substantial contributions from O.G. Venture Partners and existing investors such as Atomico, General Catalyst, and Lakestar. New players like Liberty City Ventures, Positive Sum, and BDT & MSD also joined the backing, following a $260 million Series B round earlier this year.
Founded by Spotify's Daniel Ek and Hjalmar Nilsonne, Neko Health is positioning itself as a transformative force in health technology, aimed at enhancing individual health awareness and action. Central to their offering is the Neko Health Scan, an extensive, non-invasive assessment that collects millions of health data points in just 60 minutes. The service is priced at £299 in the UK and 2,750 SEK in Sweden.
The Neko Health Scan utilizes proprietary sensors and blood analysis to evaluate various health parameters, including skin integrity, pre-diabetes biomarkers, and potential risks linked to metabolic syndrome, heart attacks, and strokes. Results are returned quickly and discussed with medical professionals during a follow-up consultation, equipping consumers with personalized insights and actionable guidance.
Recent Advancements in Scanning Technology
Only three weeks prior to this funding announcement, Neko Health launched its most ambitious scan enhancement yet. The introduction of body composition metrics, now captured during the scan and reviewed by clinicians, enables members to gain a more comprehensive understanding of their health, providing continuous insight beyond the initial assessment. This reflects Neko's commitment to ongoing innovation, supported by their ability to maintain complete control over their technology stack.
Recently, Neko opened a clinic in Stockholm, outfitted with next-generation medical devices—including Derma-2, Echo-2, and Spectrum-2. These upgrades promise to enhance health signal acquisition related to skin, heart, and circulation, while greater automation in operations allows clinical staff to better focus on patient care. This advanced hardware will soon be rolled out across all Neko locations.
Future Directions and Market Expansion
According to Hjalmar Nilsonne, Co-Founder and CEO of Neko Health, this funding enables the company to embark on its first venture into the US market while continuing investment in research and scalable health technologies. He emphasizes their track record of retaining members after their initial scans, with many observing positive changes in their health metrics upon return.
Bejul Somaia, Global Partner at Lightspeed Venture Partners, remarked on Neko Health’s impressive gains and potential, noting their approach to a vast market and consumer enthusiasm for their technology. Somaia believes the company stands among the most significant healthcare innovators of our time.
Tim Ferriss, the bestselling author behind The 4-Hour Body, highlighted the unique simplicity offered by Neko, emphasizing the efficient and thorough nature of the health evaluations available to clients. He’s been deeply involved with the company's R&D process and is enthusiastic about what lies ahead.
Since beginning its operations in February 2023, Neko Health has rolled out its services in Sweden and the UK, expanding to key cities like Manchester and multiple spots in London. The company reports over 350,000 individuals have registered for a scan, with more than 100,000 completing one. Impressively, around 75 percent of members have opted to book follow-up scans for the following year during their appointments.
Recent data showcases the impact of early detection: three out of four returning members who had previously identified severe or life-threatening conditions are enjoying better health status. Five out of seven key health indicators demonstrated statistically significant improvements between initial and subsequent scans.
As part of the Series C funding process, David Ofer from O.G. Venture Partners will take a seat on Neko’s Board of Directors, pending regulatory approval. This strategic move might well bolster Neko’s rapid growth in the preventive healthcare space.
